Evaluation of dengue antiviral candidates in vivo in mouse model

Satoru Watanabe, Subhash G. Vasudevan

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

1 Citation (Scopus)


In vivo evaluation of antiviral compounds can serve as criteria in the drug discovery process for selection of compounds that are suitable to enter late preclinical studies and further development. Dengue virus serotypes 1–4 can infect and replicate in the interferon type I and type II receptor deficient mice (AG129). Here we describe the use of a mouse-adapted dengue 2 virus strain (S221) that has been used to develop a robust lethal model of infection. Treatment with small molecule inhibitors of DENV replication at the time of infection or delayed treatment up to 48 h post infection can result in measurable protection that reflects the efficacy of the tested compound.

Original languageEnglish
Title of host publicationDengue
Subtitle of host publicationMethods and Protocols
EditorsRadhakrishnan Padmanabhan, Subhash G. Vasudevan
Place of PublicationNew York
PublisherHumana Press
Number of pages10
ISBN (Electronic)9781493903481
ISBN (Print)9781493903474
Publication statusPublished - 2014
Externally publishedYes

Publication series

NameMethods in Molecular Biology
PublisherHumana Press
ISSN (Print)1064-3745


  • 4G2 antibody
  • Antibody-dependent enhanced infection
  • Dengue antiviral testing
  • Dengue mouse model
  • Virus quantification by plaque assay

Cite this

Watanabe, S., & Vasudevan, S. G. (2014). Evaluation of dengue antiviral candidates in vivo in mouse model. In R. Padmanabhan, & S. G. Vasudevan (Eds.), Dengue: Methods and Protocols (pp. 391-400). (Methods in Molecular Biology). Humana Press. https://doi.org/10.1007/978-1-4939-0348-1_24